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ABSTRACT
Background: Although subcutaneous immunotherapy may cure allergic diseases, it is not commonly used in
Japan because of the pain and risk of anaphylactic shock. Sublingual immunotherapy(SLIT)overcomes these
limitations and although it is the most advanced form of local immunotherapy for clinical application, it is not
used in Japan nor has it been extensively studied．
Methods: After obtaining approval from the Ethics Committee of Nippon Medical School and informed con-
sent from five patients with cedar pollinosis(one man, four women ; age range, 38―66 years), administration of
a therapeutic extract was started in July 2001 or later(mean treatment period, 13.4 months). The clinical effi-
cacy of SLIT and its influence on the quality of life, as measured by the Japanese Allergic Rhinitis QOL Stan-
dard Questionnaire, and the incidence of side effects were evaluated in 2003．
Results: Between February and April the mean severity score was 1.44 in the patients undergoing SLIT and
1.86 in the patients undergoing pharmacotherapy, and the respective mean QOL total scores during the sea-
son were 3.82 and 10.0. Neither systemic nor local side effects occurred during SLIT．
Conclusions: SLIT is safe and effective for Japanese cedar pollinosis．
KEY WORDS
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INTRODUCTION
Subcutaneous injection immunotherapy is a painful
procedure and has the risk of anaphylactic shock as a
side effect, which is why it is not commonly used in
Japan . To overcome these limitations , patients in
Europe and the United States can undergo local im-
munotherapy in which the antigen is administered to
the nasal, intestinal or tracheal mucosa, and of these,
sublingual immunotherapy ( SLIT ) is the most ad-
vanced clinical application. Placebo-control studies of
SLIT against house dust,1-3 grass,4-7 weeds8 and Pa-
rietaria 9,10 have demonstrated a marked improve-
ment in clinical symptoms after immunotherapy com-
pared with placebo , and a significantly lower inci-
dence of side effects than with injection immunother-
apy. In Japan, immunotherapy consists of subcutane-
ous injection only and local immunotherapy is not
used in clinical practice. Other than our pilot study,11
SLIT has not been investigated in Japan. In the pre-
sent study conducted in 2003 we evaluated the clini-
cal efficacy of SLIT, its influence on the quality of life
(QOL)and the incidence of side effects in patients
with cedar pollinosis.
CLINICAL SUMMARY
SUBJECTS
After the protocol was approved by the Ethics Com-
mittee of Nippon Medical School and informed con-
sent was given by five patients with cedar pollinosis
(one man, four women ; age range, 38―66 years(Ta-
ble 1)), administration of a therapeutic extract was
started.
The main antigen was cedar and none of the pa-
tients had other allergic diseases or double sensitiza-
tion with other antigens that would influence the
evaluation of the treatment response during the cedar
pollen season. Treatment was started in July 2001 or
later, and clinical efficacy was evaluated in April 2003
(mean treatment period, 13.4 months).
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PharmacotherapySLIT
45.047.3Age (mean)
Sex
44female
11male
13.4 months
Duration of SLIT
 (mean) 
Severity
00Mild
42Moderate
13Severe
Table 1　Profile of patients
4th week
1：500
3rd week
1：500
2nd week
1：5000
1st week
1：50000
20 drops1 drop1 drop1 drop1st day
2 drops2 drops2 drops2nd day
4 drops3 drops3 drops3rd day
8 drops4 drops4 drops4th day
20 drops12 drops6 drops6 drops5th day
16 drops8 drops8 drops6th day
20 drops10 drops10 drops7th day
Table 2　Schedule of sublingual administration
The pharmacotherapy group consisted of five pa-
tients with cedar pollinosis who consulted the outpa-
tient clinic of the Department of Otorhinolaryngology
at Nippon Medical School Hospital during the same
period(one man, four women ; age range, 36―53 years
(Table 1)).
METHODS
Japanese cedar antigen extract(1 : 20)(Hollister-Stier
Laboratories LLC, Spokane, WA, USA)was diluted
prior to use, but because it is not standardized, there
are no data about its major allergen content. In our
preliminary study , the concentration of the major
Japanese cedar pollen allergen, Cry j 1, was regarded
as being 7.7―16.5 μgml.12 Crumbs containing the an-
tigen extract were placed under the tongue for ap-
proximately 2 min and then spat out(‘sublingual spit-
out’ ) . The subjects attended the outpatient clinic ,
weekly from week 1 to week 3 and then fortnightly
from week 4 of treatment, where they obtained the
therapeutic extract and administered it at home in in-
creasing doses(Table 2).
Clinical Symptoms(Nasal Symptom Score)
Nasal allergic symptoms were evaluated from patient
diaries and symptomseverity scores were calculated
according to the Japanese Practice Guideline for Al-
lergic Rhinitis(4th edition).13 The most severe status
was scored as 4, severe status as 3, moderate status
as 2, and mild status as 1(Table 3).
Medication Score
In the drug therapy group, the various medications
were also scored according to the guideline13 as fol-
lows : first- or second-generation antihistamines and
mast cell stabilizers , 1 point ; topical steroids , 2
points ; vasoconstrictor or anticholinergic nasal drop
preparations, 1 point ; antihistaminic eye drop prepa-
rations, 1 point ; steroid eye spray preparations , 2
points ; the period during which the dose is in-
creased, 0.5 points ; the maintenance dose, 1 point ;
and mixed preparation of an antihistaminic agent and
betamethasone, 3 points(Table 4).
Evaluation of QOL
We evaluated changes in the subjects’ QOL during
the cedar pollen season using the Japanese Allergic
Rhinitis QOL Standard Questionnaire ( JRQLQ ;
2002 ) , 14 which has three parts : ( I ) nasalocular
symptoms,(II)17 questions about QOL and(III)a com-
prehensive evaluation(face scale).
The QOL questions investigated issues in six do-
mains(‘daily life’, ‘outdoor life’, ‘social life’, ‘sleep’, ‘fa-
tigue’ and ‘ emotion’ ) , such as ‘ interference with
study, work, or housework’, ‘lack of concentration’,
‘decline in thinking power’, ‘inconvenience with read-
ing and newspapers’, ‘debilitating memory loss’, ‘in-
terference with outdoor activities such as sports, pic-
nic, etc’, ‘limitation on going out’, ‘interference with
social activities’, ‘interference with conversationtele-
phone conversation’, ‘embarrassment from presumed
public attention’ , ‘sleep disorder’ , ‘ feeling of weari-
ness’ , ‘ fatigue’ , ‘nervousness’ , ‘ frustrated’ , ‘gloomi-
ness’ and ‘ lack of satisfaction with daily life’ . Re-
sponses were evaluated using five grades．
PATHOLOGICAL FINDINGS
In 2003, the amount of cedar pollen in Chiyoda-ku,
central Tokyo, was 3,622 grainscm2, which was simi-
lar to the annual average(according to a survey con-
ducted by the Bureau of Public Health Tokyo Metro-
politan Government).
CHANGES IN CLINICAL SYMPTOMS ( NASAL
SYMPTOM SCORE)
As shown in Table 5 the mean symptom scores in the
SLIT group for sneezing, nasal discharge, nasal ob-
struction , and ocular symptoms between February
and April were 1.07, 1.30, 0.56, and 0.39, respectively.
All scores were highest in March and rapidly re-
turned to the February values in April. The respective
mean symptom scores in the pharmacotherapy group
were 1.07, 1.76, 1.01, and 0.80(Table 5). All scores
were highest in March, as in the SLIT group, but in
April there was a prolonged interval until symptoms
were relieved.
The mean severity scores between February and
April were 1.44 in the SLIT group and 1.86 in the
pharmacotherapy group(Table 6).
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Table 3 Criteria for symptom score and severity score 
Nasal obstruction
No. of nose blows
per day
No. of sneezing atacks
per day
Grade
Complete
(al day)
>20>20
Most severe
(4 points)
Severe
(considerable amount of mouth breathing required)
11―2011―20
Severe
(3 points)
Marked
(frequent mouth breathing)
6―106―10
Moderate
(2 points)
Present
(no mouth breathing)
 1―51―5
Mild
(1 point)
None00
No symptoms
(0 point)
1 point
1st, 2nd generation anti-histamines, mast cel 
stabilizers
2 pointsTopical steroids 
1 pointDecongestant, anti-cholinergic agents 
1 pointOcular anti-histamines
2 pointsOcular steroids
Specific immunotherapy 
0.5 pointsDuring step up
1 pointDuring maintenance dose
3 pointsOral steroids and anti-histamines
Table 4 Criteria for medication score
CHANGES IN THE MEDICATION SCORE
The mean medication scores between February and
April were 0.21 in the SLIT group and 1.85 in the
pharmacotherapy group(Table 7).
CHANGES IN THE QOL
The mean QOL total scores during the pollen season
were 3.82 in the SLIT group and 10.0 in the drug ther-
apy group(Table 8).
SIDE EFFECTS
Neither systemic nor local side effects occurred dur-
ing SLIT.
DISCUSSION
The mechanism of action for SLIT , or for conven-
tional allergen immunotherapy, is still unclear, but for
allergen-specific immunotherapy, reduction of effec-
tor cells15,16 and blocking antibody17-20 have been the
conventional theories. Recently, however, it has be-
come widely accepted that immunotherapy may mod-
ify the T cell response to natural allergens because of
T cell anergy andor immune deviation.21-24 For SLIT
in particular, allergen administered to the oral mu-
cosa accumulates in the submandibular lymph node,
in which the immune response occurs25 and peaks at
approximately 2 h after administraton.26 Of the local
immunotherapy modalities, SLIT is the most effective
with a lower incidence of side effects, which complies
with the WHO position paper on allergen immuno-
therapy requiring a new route of administration, such
as local immunotherapy, and treatment that does not
cause anaphylaxis, such as peptide therapy.27 How-
ever, only subcutaneous immunotherapy is used for
Japanese cedar pollinosis and other than our pilot
study,11 and the present report, SLIT is an unknown
treatment.
Approximately 13% of the Japanese population are
affected by Japanese cedar pollinosis28 and the pro-
portion of severe status patients is higher than with
grass or ragweed pollinosis, which are the represen-
tative conditions in other countries , and the symp-
toms persist for about 3 months, becoming a social is-
sue. When the amount of pollen increases, patients
show more severe symptoms, and the number of se-
vere status patients is greatest in mid-March(late sea-
son)when the pollen count reaches its peak. Substan-
tial antigen exposure enhances the antigen-antibody
reaction in the airways ( airway hypersensitivity ) ,
which is the mechanism involved in severe pollinosis,
and immunotherapy with antigen-specific effects may
control the exacerbation of the symptoms in the latter
half of the cedar pollen season by inhibiting antigen-
related enhancement of nasal mucosal hypersensitiv-
ity. In the present study, SLIT both inhibited the ex-
acerbation of symptoms in the latter half of the sea-
son and reduced their severity throughout the sea-
son. Furthermore, there were neither local nor sys-
temic side effects, as reported elsewhere for other an-
tigens．
SLIT for cedar pollinosis is a new therapy and in
the future SLIT may by indicated for patients with na-
sal allergy caused by other allergens such as house
dust mites or animal dander through improvement of
the administration schedule and establishing the
dose at which the most potent effects are achieved.
Therefore, a multicenter study involving a large num-
ber of patients should be conducted.
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Table 5　Monthly mean change in symptom score
Mean of
3 months
Apr.Mar.Feb.
1.071.361.350.44Pharmacotherapy
Score of sneezing
1.070.871.480.84SLIT
1.762.002.191.02Pharmacotherapy
Score of nasal discharge
1.301.161.790.91SLIT
1.011.151.370.48Pharmacotherapy
Score of nasal obstruction
0.560.490.860.31SLIT
0.800.761.140.46Pharmacotherapy
Eye symptom score
0.390.210.680.26SLIT
Table 6　Monthly mean change in severity score
Mean of
3 months
Apr.Mar.Feb.
1.862.132.251.14Pharmacotherapy
Severity score
1.441.261.921.11SLIT
Table 7　Monthly mean change in medication score
Mean of
3 months
Apr.Mar.Feb.
1.852.131.901.49Pharmacotherapy
Medication score
0.210.120.430.07SLIT
Table 8　Monthly mean change in QOL score
Mean of
3 months
Apr.Mar.Feb.
10.07.216.86.0Pharmacotherapy
QOL score
3.823.825.81.67SLIT
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